EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Economic Profit
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= 5,919 – 8.93% × 61,356 = 441
The analysis of economic value added reveals a period of significant volatility, characterized by a sharp decline in profitability between 2021 and 2023, followed by a gradual recovery toward value creation by 2025.
- Net Operating Profit After Taxes (NOPAT)
- A substantial contraction in operating profitability is evident, with NOPAT falling from 12,362 million USD in 2021 to a low of 3,292 million USD in 2023. This represents a precipitous decline that severely impacted the ability to cover capital costs. However, a recovery trend emerged in 2024 and 2025, with figures rising to 4,563 million USD and 5,919 million USD, respectively, although levels remain well below the 2021 peak.
- Cost of Capital and Invested Capital
- The cost of capital has exhibited a consistent upward trajectory, increasing from 8.02% in 2021 to 8.93% by 2025. Simultaneously, invested capital has trended downward, decreasing from 95,922 million USD in 2021 to 61,356 million USD in 2025. The reduction in the capital base served to lower the absolute dollar amount of the capital charge, partially offsetting the impact of the rising percentage cost of capital.
- Economic Profit Trajectory
- Economic profit shifted from a state of value creation to value destruction and back again. Positive economic profit was recorded in 2021 and 2022, reaching 4,671 million USD and 4,509 million USD. A critical pivot occurred in 2023, where economic profit turned negative at -2,681 million USD, indicating that NOPAT was insufficient to cover the cost of invested capital. While the deficit narrowed in 2024 to -1,535 million USD, the company successfully returned to a positive economic profit of 441 million USD by 2025.
The overall trend indicates a transition from high-magnitude value creation to a period of financial distress and eventual stabilization. The return to positive economic profit in 2025 was driven by a combination of recovering operating profits and a leaner capital structure.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in restructuring reserve.
3 Addition of increase (decrease) in equity equivalents to net earnings attributable to AbbVie Inc..
4 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= 883 × 3.50% = 31
5 2025 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= 2,924 × 21.00% = 614
6 Addition of after taxes interest expense to net earnings attributable to AbbVie Inc..
7 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= 266 × 21.00% = 56
8 Elimination of after taxes investment income.
Net earnings attributable to AbbVie Inc. exhibited an initial increase from 2021 to 2022, followed by a substantial decline in 2023 and a slight recovery in 2024 and 2025. However, the trend in net operating profit after taxes (NOPAT) presents a different pattern. NOPAT decreased from 2021 to 2023, then increased significantly in 2024 and 2025.
- NOPAT Trend
- NOPAT began at US$12,362 million in 2021, decreasing to US$11,543 million in 2022, representing a decline of approximately 6.7%. A more pronounced decrease occurred in 2023, with NOPAT falling to US$3,292 million. This represents a substantial reduction of over 71% from the 2022 value. A recovery is then observed in 2024, with NOPAT rising to US$4,563 million, and continuing upward in 2025 to reach US$5,919 million. The 2025 value, while representing a significant improvement from 2023, remains below the levels seen in 2021 and 2022.
The divergence between the trends in net earnings and NOPAT suggests potential shifts in the company’s capital structure or non-operating items. While net earnings decreased significantly in 2023, the NOPAT decline was even more substantial, indicating that factors beyond core operating profitability contributed to the reduction in net income. The subsequent recovery in NOPAT, exceeding the recovery in net earnings, suggests improvements in operational efficiency or changes in the cost of capital may be influencing the results.
- Relationship between NOPAT and Net Earnings
- In 2021 and 2022, NOPAT was consistently higher than net earnings attributable to AbbVie Inc. However, this relationship changed in 2023 and 2024, where net earnings exceeded NOPAT. By 2025, net earnings and NOPAT were relatively close, but net earnings remained slightly higher. This difference could be attributed to items such as interest expense, taxes, and other non-operating income or expenses.
The substantial fluctuations in NOPAT warrant further investigation to understand the underlying drivers. A detailed analysis of the components of NOPAT, including operating revenue, operating expenses, and tax rates, would be necessary to pinpoint the specific factors contributing to these changes.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Cash Operating Taxes
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The reported income tax expense and cash operating taxes exhibit distinct trends over the five-year period. Income tax expense fluctuates considerably, while cash operating taxes generally increase, though with notable variations.
- Income Tax Expense
- Income tax expense increased from US$1,440 million in 2021 to US$1,632 million in 2022, representing a rise of approximately 13.3%. A subsequent decrease was observed in 2023, with expense falling to US$1,377 million. A significant shift occurred in 2024, resulting in a tax benefit of US$570 million. This was followed by a substantial increase in expense to US$2,364 million in 2025. The volatility suggests potential impacts from changes in tax laws, deferred tax asset adjustments, or significant shifts in pre-tax income.
- Cash Operating Taxes
- Cash operating taxes demonstrate an overall upward trend, although not consistently. The amount rose from US$2,843 million in 2021 to US$3,997 million in 2022, an increase of approximately 40.6%. Further growth was seen in 2023, reaching US$4,625 million. A considerable decline occurred in 2024, with cash taxes decreasing to US$1,339 million. The final year, 2025, shows a recovery to US$3,414 million. The fluctuations in cash taxes are likely influenced by timing differences between income tax expense and actual cash payments, as well as potential tax planning strategies.
- Relationship between Income Tax Expense and Cash Operating Taxes
- A divergence is apparent between the two measures. While income tax expense is reported on the income statement based on accounting standards, cash operating taxes reflect the actual cash outflows for taxes. The significant difference in 2024, where an income tax benefit is recorded alongside a cash outflow, indicates substantial deferred tax impacts or tax credits being utilized. The generally higher level of cash taxes compared to income tax expense throughout the period suggests the company may be utilizing tax loss carryforwards or experiencing temporary differences that result in higher cash payments than reported expense.
The observed patterns warrant further investigation into the underlying drivers of these fluctuations, particularly the significant changes in 2024 and 2025, to fully understand their implications for the company’s financial position and future cash flows.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Invested Capital
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of restructuring reserve.
4 Addition of equity equivalents to stockholders’ equity (deficit).
5 Removal of accumulated other comprehensive income.
6 Subtraction of construction in progress.
7 Subtraction of available-for-sale investment securities.
The reported invested capital demonstrates a declining trend over the five-year period. Total reported debt & leases and stockholders’ equity both contribute to the calculation of invested capital, and changes in these components influence the overall trend.
- Invested Capital Trend
- Invested capital decreased from US$95,922 million in 2021 to US$61,356 million in 2025. The most significant decrease occurred between 2022 and 2023, falling from US$82,134 million to US$68,204 million. A smaller decrease was observed between 2021 and 2022. A slight increase occurred between 2023 and 2024, followed by a further decrease in 2025.
- Debt & Leases
- Total reported debt & leases decreased from US$77,575 million in 2021 to US$64,191 million in 2022, continuing to US$60,286 million in 2023. An increase to US$68,019 million was noted in 2024, followed by a marginal increase to US$68,379 million in 2025. While fluctuating, the level of debt remained relatively stable between 2024 and 2025.
- Stockholders’ Equity
- Stockholders’ equity increased from US$15,408 million in 2021 to US$17,254 million in 2022. However, a substantial decline was observed in subsequent years, decreasing to US$10,360 million in 2023, US$3,325 million in 2024, and ultimately reaching a deficit of US$-3,270 million in 2025. This negative equity position in the final year represents a significant shift.
The decrease in invested capital appears to be primarily driven by the substantial reduction in stockholders’ equity, particularly in the later years of the period. While debt levels decreased initially, they stabilized and even increased slightly in the most recent years, suggesting that debt reduction is not the primary driver of the overall decline in invested capital. The transition to negative stockholders’ equity in 2025 is a notable development that warrants further investigation.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Cost of Capital
AbbVie Inc., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 397,502) | 397,502) | ÷ | 463,020) | = | 0.86 | 0.86 | × | 9.85% | = | 8.46% | ||
| Debt and finance lease obligations3 | 64,635) | 64,635) | ÷ | 463,020) | = | 0.14 | 0.14 | × | 4.21% × (1 – 21.00%) | = | 0.46% | ||
| Operating lease liability4 | 883) | 883) | ÷ | 463,020) | = | 0.00 | 0.00 | × | 3.50% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 463,020) | 1.00 | 8.93% | ||||||||||
Based on: 10-K (reporting date: 2025-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 340,484) | 340,484) | ÷ | 404,066) | = | 0.84 | 0.84 | × | 9.85% | = | 8.30% | ||
| Debt and finance lease obligations3 | 62,707) | 62,707) | ÷ | 404,066) | = | 0.16 | 0.16 | × | 4.05% × (1 – 21.00%) | = | 0.50% | ||
| Operating lease liability4 | 875) | 875) | ÷ | 404,066) | = | 0.00 | 0.00 | × | 3.30% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 404,066) | 1.00 | 8.80% | ||||||||||
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 310,458) | 310,458) | ÷ | 367,703) | = | 0.84 | 0.84 | × | 9.85% | = | 8.32% | ||
| Debt and finance lease obligations3 | 56,344) | 56,344) | ÷ | 367,703) | = | 0.15 | 0.15 | × | 3.57% × (1 – 21.00%) | = | 0.43% | ||
| Operating lease liability4 | 901) | 901) | ÷ | 367,703) | = | 0.00 | 0.00 | × | 3.00% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 367,703) | 1.00 | 8.76% | ||||||||||
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 267,728) | 267,728) | ÷ | 326,497) | = | 0.82 | 0.82 | × | 9.85% | = | 8.08% | ||
| Debt and finance lease obligations3 | 57,849) | 57,849) | ÷ | 326,497) | = | 0.18 | 0.18 | × | 3.42% × (1 – 21.00%) | = | 0.48% | ||
| Operating lease liability4 | 920) | 920) | ÷ | 326,497) | = | 0.00 | 0.00 | × | 2.60% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 326,497) | 1.00 | 8.56% | ||||||||||
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 254,754) | 254,754) | ÷ | 339,401) | = | 0.75 | 0.75 | × | 9.85% | = | 7.40% | ||
| Debt and finance lease obligations3 | 83,756) | 83,756) | ÷ | 339,401) | = | 0.25 | 0.25 | × | 3.17% × (1 – 21.00%) | = | 0.62% | ||
| Operating lease liability4 | 891) | 891) | ÷ | 339,401) | = | 0.00 | 0.00 | × | 2.40% × (1 – 21.00%) | = | 0.00% | ||
| Total: | 339,401) | 1.00 | 8.02% | ||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | 441) | (1,535) | (2,681) | 4,509) | 4,671) | |
| Invested capital2 | 61,356) | 69,263) | 68,204) | 82,134) | 95,922) | |
| Performance Ratio | ||||||
| Economic spread ratio3 | 0.72% | -2.22% | -3.93% | 5.49% | 4.87% | |
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| Amgen Inc. | 6.25% | -0.54% | 2.28% | 6.80% | 6.80% | |
| Bristol-Myers Squibb Co. | 5.66% | -22.01% | 1.55% | -1.21% | 1.09% | |
| Danaher Corp. | -10.71% | -10.87% | -11.64% | -6.63% | -5.80% | |
| Eli Lilly & Co. | 30.14% | 14.49% | 1.42% | 8.52% | 10.19% | |
| Gilead Sciences Inc. | 12.61% | -10.47% | 2.85% | -0.27% | 6.76% | |
| Johnson & Johnson | 11.55% | 1.88% | 0.03% | 5.29% | 10.35% | |
| Merck & Co. Inc. | 10.49% | 13.36% | -8.94% | 11.24% | 11.41% | |
| Pfizer Inc. | -3.69% | -3.37% | -9.48% | 17.97% | 11.14% | |
| Regeneron Pharmaceuticals Inc. | 13.82% | 16.64% | 13.44% | 18.80% | 62.56% | |
| Thermo Fisher Scientific Inc. | -7.45% | -8.25% | -8.72% | -6.97% | -4.95% | |
| Vertex Pharmaceuticals Inc. | 20.79% | -22.86% | 11.09% | 13.84% | 15.05% | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × 441 ÷ 61,356 = 0.72%
4 Click competitor name to see calculations.
The financial trajectory from 2021 to 2025 reveals a period of significant volatility in value creation, characterized by an initial phase of positive economic returns, a mid-period decline into value destruction, and a subsequent return to positive territory by the end of the analyzed timeframe.
- Economic Spread Ratio
- The economic spread ratio exhibited a peak of 5.49% in 2022 after starting at 4.87% in 2021, indicating that the return on invested capital exceeded the cost of capital. However, a sharp reversal occurred in 2023, with the ratio dropping to -3.93%, signaling a period where the cost of capital outweighed returns. A gradual recovery followed, with the ratio improving to -2.22% in 2024 and eventually returning to a positive state of 0.72% by December 31, 2025.
- Economic Profit
- Economic profit mirrored the trends of the spread ratio, moving from a high of 4,671 million US dollars in 2021 to a substantial deficit of -2,681 million US dollars in 2023. While the losses narrowed to -1,535 million US dollars in 2024, the trend culminated in a return to profitability in 2025, reaching 441 million US dollars. This shift indicates a restoration of the company's ability to generate returns above its required capital threshold.
- Invested Capital
- A consistent downward trend in invested capital is observed over the five-year period. Capital levels decreased from 95,922 million US dollars in 2021 to 61,356 million US dollars in 2025. Aside from a marginal increase in 2024 to 69,263 million US dollars, the overall reduction in the capital base suggests a strategic contraction or optimization of assets used to generate economic value.
The correlation between the declining invested capital and the fluctuating economic spread ratio suggests that while the capital base was reduced, the efficiency of that capital varied significantly. The return to a positive economic spread ratio in 2025, despite a lower capital base than in 2021, indicates an improvement in capital efficiency relative to the cost of capital.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Economic Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | 441) | (1,535) | (2,681) | 4,509) | 4,671) | |
| Net revenues | 61,160) | 56,334) | 54,318) | 58,054) | 56,197) | |
| Performance Ratio | ||||||
| Economic profit margin2 | 0.72% | -2.73% | -4.94% | 7.77% | 8.31% | |
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| Amgen Inc. | 10.42% | -1.06% | 5.93% | 10.90% | 11.26% | |
| Bristol-Myers Squibb Co. | 6.96% | -28.55% | 2.33% | -1.87% | 1.88% | |
| Danaher Corp. | -32.81% | -33.56% | -38.22% | -16.48% | -14.50% | |
| Eli Lilly & Co. | 22.94% | 11.51% | 1.22% | 7.25% | 9.40% | |
| Gilead Sciences Inc. | 18.67% | -16.23% | 4.86% | -0.46% | 11.95% | |
| Johnson & Johnson | 16.94% | 2.25% | 0.03% | 6.34% | 10.83% | |
| Merck & Co. Inc. | 15.81% | 16.54% | -10.41% | 14.02% | 16.57% | |
| Pfizer Inc. | -8.24% | -7.17% | -24.66% | 19.67% | 11.89% | |
| Regeneron Pharmaceuticals Inc. | 12.76% | 14.59% | 12.26% | 18.93% | 42.30% | |
| Thermo Fisher Scientific Inc. | -15.75% | -15.79% | -17.42% | -12.85% | -10.07% | |
| Vertex Pharmaceuticals Inc. | 18.34% | -18.76% | 14.88% | 20.42% | 18.65% | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Net revenues
= 100 × 441 ÷ 61,160 = 0.72%
3 Click competitor name to see calculations.
The financial trajectory between 2021 and 2025 is characterized by a period of significant volatility in economic value creation, transitioning from positive economic profit to a two-year period of value destruction before returning to a positive state.
- Economic Profit Trends
- A substantial decline in economic profit is observed starting in 2023, where the value shifted from a positive 4,509 million USD in 2022 to a deficit of 2,681 million USD. This negative trend persisted through 2024, although the magnitude of the loss narrowed to 1,535 million USD. By the end of 2025, a recovery is evident as the figure returned to positive territory at 441 million USD, indicating that the company once again generated returns exceeding its cost of capital.
- Net Revenue Performance
- Net revenues exhibited relative stability with a fluctuating growth pattern. Following an increase to 58,054 million USD in 2022, a contraction occurred in 2023, coinciding with the period of maximum economic profit loss. However, a consistent recovery trend followed, with revenues climbing to 56,334 million USD in 2024 and reaching a period high of 61,160 million USD in 2025.
- Economic Profit Margin Analysis
- The economic profit margin mirrors the volatility seen in absolute economic profit. The margin decreased from a peak of 8.31% in 2021 to 7.77% in 2022, before collapsing to -4.94% in 2023. A gradual improvement in capital efficiency is observed from 2024 through 2025, with the margin rising from -2.73% to 0.72%. This recovery suggests a restoration of the company's ability to generate surplus value relative to its revenue base.
Overall, the period reflects a critical downturn in value creation centered around 2023 and 2024, followed by a strategic recovery in both top-line revenue and economic profitability by the end of 2025.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?